Journal
CLINICAL KIDNEY JOURNAL
Volume 2, Issue 2, Pages 152-154Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ndtplus/sfn195
Keywords
5-fluorouracil; gimeracil; haemodialysis; S-1
Categories
Ask authors/readers for more resources
S-1 and cisplatin are used as one of the first-line chemotherapies for gastric cancer in Japan. The plasma concentration of 5-fluorouracil (5-FU) is increased in patients with renal dysfunction because gimeracil in S-1 inhibits the degradation of 5-FU and about 50% of gimeracil is excreted in the urine. We describe a 35-year-old man with acute kidney injury-while taking S-1 and cisplatin for advanced gastric cancer and who presented severe adverse effects of 5-FU. This case report describes the evolution of the plasma concentrations of 5-FU with haemodialysis along with a decrease in the adverse drug effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available